| Document |
Document Title |
|
WO/2022/019535A1 |
The present specification relates to a compound of chemical formula 1, and an organic light-emitting device comprising same.
|
|
WO/2022/017975A1 |
Compounds of the formula (I) wherein the substituents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and t...
|
|
WO/2022/020716A1 |
The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.
|
|
WO/2022/020647A1 |
Combinatorial therapeutic systems can include a systemic, centrally and peripherally acting analgesics and an artificial sensory experience. Methods for treating and/or mitigating pain can include receiving a systemic, centrally and peri...
|
|
WO/2022/020714A1 |
Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such...
|
|
WO/2022/016898A1 |
The present application provides an organic compound, an organic electroluminescence device and an electronic apparatus. The chemical structure of the organic compound in the present application comprises an adamantane spirofluorene ring...
|
|
WO/2022/020747A1 |
The present disclosure provides crystalline polymorphs of 5-aza-4'-thio-2'-deoxycytidine. The crystalline polymorphs may be formulated in a pharmaceutical composition, optionally in combination with an additional chemotherapeutic agent. ...
|
|
WO/2022/020342A1 |
Provided herein are compounds of formula (V) that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease.
|
|
WO/2022/020738A1 |
Provided herein are compounds comprising a three-ring core and pharmaceutically acceptable salts, solvates, tautomers, isotopes, or isomers thereof. Also provided herein are methods of inhibiting a component of the sterol regulatory elem...
|
|
WO/2022/015624A1 |
This present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I) and ph...
|
|
WO/2022/013417A1 |
Compounds of the formula (I), wherein the substituents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and ...
|
|
WO/2022/014857A1 |
The present invention provides a novel compound and an organic light-emitting element comprising same.
|
|
WO/2022/015979A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2022/013378A1 |
The present invention relates to compounds of general formula (I) inhibiting lysophosphatidic acid receptor 1 (LPA1), particularly the invention relates to compounds that are Ami do cyclohexane acid derivatives, methods of preparing such...
|
|
WO/2022/007743A1 |
Provided is a mucosal administration dosage form, in particular a nasal administration dosage form, containing a compound of formula I or a pharmaceutically acceptable salt, a solvate, or a prodrug thereof. The mucosal administration dos...
|
|
WO/2022/007909A1 |
The present application relates to the technical field of organic material and provides a nitrogen-containing compound, an electronic component and an electronic device. The nitrogen-containing compound has a structure as shown in formul...
|
|
WO/2022/007875A1 |
The present invention relates to the use of a compound of formula (I) or a pharmacologically acceptable salt, a stereoisomer, an active metabolite, a prodrug, a crystal or a solvate thereof or a composition thereof in the preparation of ...
|
|
WO/2022/010937A1 |
Pharmaceutically active benzothiophene compounds and their pharmaceutically acceptable salts and salt mixtures and pharmaceutically acceptable compositions for the treatment of mental disorders or for mental enhancement, including for en...
|
|
WO/2022/010305A1 |
The present invention provides: a novel compound capable of improving the light-emitting efficiency, stability, and lifespan of an element; an organic electronic element using same; and an electronic device thereof.
|
|
WO/2022/010537A1 |
Provided herein are small molecules that bind to GAS41 and inhibit GAS41 activity, and methods of use thereof for the treatment of cancer.
|
|
WO/2022/008975A1 |
Imide-linked polymeric photoinitiators and compositions useful in the preparation of such polymeric photoinitiators and to the use of these polymers in, e.g., UV curable adhesives, UV curable coating compositions and UV curable encapsula...
|
|
WO/2022/007461A1 |
Disclosed is an immunomodulator, and the present invention specifically relates to a compound for inhibiting IL-17A and an application of the compound serving as the immunomodulator in the preparation of a drug. Disclosed is an applicati...
|
|
WO/2022/003491A1 |
Provided is a light-emitting device that is highly efficient at emitting light. Provided is a light-emitting device wherein: said light-emitting device has a cathode, an anode, and an EL layer positioned between the same; the EL layer ha...
|
|
WO/2022/000031A1 |
Described herein are compounds that are inhibitors of p21-activated kinases (PAKS). In particular, the compounds described herein are demonstrated to be selective PAK4 inhibitors. The compounds described herein are also demonstrated to r...
|
|
WO/2022/002077A1 |
Disclosed in the present invention are an aryl aromatic heterocyclic derivative and preparation thereof and use thereof. The structure is as shown in formula I, and in this formula, the definitions of substituents are as stated in the de...
|
|
WO/2021/261856A1 |
The present specification relates to a heterocyclic compound and an organic light-emitting device comprising same.
|
|
WO/2021/263079A1 |
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds for inhibiting three prime repair exonuclease 1 ("TREX1").
|
|
WO/2021/258272A1 |
The present invention provides compounds of Formula (I) which can be used as macrophage migration inhibitory factor (MIF) inhibitors; methods for the production of the compounds of the invention; pharmaceutical compositions comprising th...
|
|
WO/2021/262693A1 |
Compounds having general formula (I) or a pharmaceutically acceptable salt, N-oxide, or hydrate thereof are provided herein. Also provided are methods of making the compounds and methods of their use, including in treatment of cancer, au...
|
|
WO/2021/261447A1 |
The present invention addresses a first problem of providing a photoelectric conversion element having high external quantum efficiency and little response variation. The present invention also addresses a second problem of providing an ...
|
|
WO/2021/259163A1 |
Provided is a 2-N-substituted fused pyrazole-type compound, specifically a one-pot synthesis method for the preparation of a 2-N-substituted indazole-type compound. After azidizing a halogen in a substrate, no post-processing is necessar...
|
|
WO/2021/261563A1 |
In the production of crops in agriculture, horticulture and the like, the occurrence of damages by pests and the like has been still a major issue, and therefore the development of novel agricultural/horticultural insecticides has been d...
|
|
WO/2021/261849A1 |
The present specification relates to a compound of chemical formula 1, and an organic light-emitting device and a composition for forming an organic material layer, comprising same.
|
|
WO/2021/261946A1 |
The present application provides a heterocyclic compound capable of greatly improving the lifespan, efficiency, electrochemical stability, and thermal stability of an organic light-emitting device, and an organic light-emitting device in...
|
|
WO/2021/223650A9 |
The present application relates to a nitrogen-containing compound. The structural formula of the nitrogen-containing compound is as shown in formula I, in which ring A and ring B are each independently selected from a benzene ring or a f...
|
|
WO/2021/259049A1 |
Disclosed are an indole derivative, a preparation method therefor and the use thereof; and a pharmaceutically acceptable salt, a hydrate, a solvate or a prodrug of the compound, preparation methods therefor and the use thereof as a thera...
|
|
WO/2021/256861A1 |
The present invention provides a novel compound represented by chemical formula 2, or a pharmaceutically acceptable salt thereof. The novel compound according to the present invention exhibits an excellent acid secretion inhibitory effect.
|
|
WO/2021/254118A1 |
Applications of an HPK1 kinase inhibitor in preventing and/or treating an animal pathogen infection. The HPK1 kinase inhibitor is a small molecule HPK1 kinase inhibitor, specifically, the compound of formula I or a pharmaceutically accep...
|
|
WO/2021/253098A1 |
This invention relates to compounds of formula (I) and salts, solvates, tautomers, N-oxides, stereoisomers, polymorphs and/or prodrugs thereof. Also disclosed is the use of the compound of formula (I) to treat necroptosis and/or inhibit ...
|
|
WO/2021/252491A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2021/252859A1 |
The disclosure provides at least one compound, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of formula (I), deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing...
|
|
WO/2021/250531A1 |
The present invention provides a compound represented by the following chemical formula I, an optical isomer or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising same: (In chemical formula I above, A...
|
|
WO/2021/252849A1 |
The disclosure provides compounds of Formula (I), deuterated derivatives of those compounds, and pharmaceutically acceptable salts of those compounds and derivatives, compositions comprising the same, and methods of using the same, inclu...
|
|
WO/2021/251433A1 |
The present disclosure provides: a composition which contains a compound represented by general formula (1) and a polymer compound, wherein the content of chloride ions relative to the total mass of the composition is less than 1.5 ppm; ...
|
|
WO/2021/251725A1 |
The present specification relates to a xanthene- or thioxanthene-based compound expressed by chemical formula 1, and an organic light-emitting device comprising same.
|
|
WO/2021/246698A1 |
The present invention provides: a compound represented by chemical formula 1; an organic electric element comprising a first electrode, a second electrode, and an organic material layer between the first electrode and the second electrod...
|
|
WO/2021/244505A1 |
The present invention relates to a compound as represented by general formula (1), and a preparation method therefor, and the use of the compound as represented by general formula (1) and an isomer, a crystal form, a pharmaceutically acc...
|
|
WO/2021/247217A1 |
The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament f...
|
|
WO/2021/244645A1 |
A novel five-membered heteroaromatic imidazole compound and use thereof in preparing a medicament for treating related diseases. Specifically, disclosed are a compound as shown in formula (III) and a pharmaceutically acceptable salt ther...
|
|
WO/2021/245055A1 |
The present invention encompasses compounds of formula (I), wherein R1a, R1b, R2a, R2b, Z, R3, R5, A, U, V, W, L and E have the meanings given in the claims and specification, their use as inhibitors of mutant Ras family proteins, pharma...
|
